Sponsors (3)
This bill increases transparency of drug manufacturers and labeling—helping patients, providers, and regulators respond faster to safety issues and simplifying import compliance—but does so at the cost of added compliance and IT burdens for industry, potential price impacts on smaller firms, and some loss of customs country-of-origin transparency that could be exploited or complicate enforcement.
Patients (especially those with chronic conditions) and hospitals can identify the original manufacturers of APIs and finished drugs via facility identifiers and barcode/QR links, enabling faster source tracing and quicker recalls/investigations to improve medication safety.
Drug manufacturers, importers, and health providers can follow FDA labeling rules for imported finished drug products instead of separate customs marking rules, simplifying compliance and reducing the risk of enforcement actions or shipment delays.
Consumers can access manufacturer and quantity information through barcode/QR links or on paper upon request, improving their ability to verify products and make informed purchasing or safety decisions.
Small drug manufacturers and distributors will face higher compliance and implementation costs for new labeling, identifiers, and IT requirements, which could raise drug prices or reduce competition.
Manufacturers and regulators must build and maintain searchable portals, QR-linking systems, and extra paperwork, creating administrative burdens and transition costs for industry and state/federal agencies.
Allowing FDA labeling to substitute for customs marking could be exploited by some importers to obscure country-of-origin information, risking reduced transparency and potential tariff loss.
Based on analysis of 3 sections of legislative text.
Requires drug and API labels (or a scannable portal) to list original manufacturers, facility locations, and unique facility identifiers and allows FDA labeling to satisfy some customs marking rules.
Official title: To amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information.
Introduced April 14, 2026 by Rich McCormick · Last progress April 14, 2026
Requires finished drug products and active pharmaceutical ingredients (APIs) to carry detailed origin and supply-chain information on packaging or via a searchable electronic portal, including the name, place of business, and a unique facility identifier for original API manufacturers and packers/distributors. Directs FDA to write implementing regulations and gives manufacturers up to one year after final rule publication before the rules apply to drugs manufactured on or after the effective date. Also amends customs law so qualifying finished drug products marked under the new FDA labeling rules can be treated as compliant with country-of-origin marking requirements under the Tariff Act, letting FDA labeling satisfy certain Customs marking rules for covered drugs.